BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 18242088)

  • 1. Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda6-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 1: exploration of 7'-substitution of benzothiadiazine.
    Zhou Y; Webber SE; Murphy DE; Li LS; Dragovich PS; Tran CV; Sun Z; Ruebsam F; Shah AM; Tsan M; Showalter RE; Patel R; Li B; Zhao Q; Han Q; Hermann T; Kissinger CR; Lebrun L; Sergeeva MV; Kirkovsky L
    Bioorg Med Chem Lett; 2008 Feb; 18(4):1413-8. PubMed ID: 18242088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 2: Variation of the 2- and 6-pyridazinone substituents.
    Zhou Y; Li LS; Dragovich PS; Murphy DE; Tran CV; Ruebsam F; Webber SE; Shah AM; Tsan M; Averill A; Showalter RE; Patel R; Han Q; Zhao Q; Hermann T; Kissinger CR; Lebrun L; Sergeeva MV
    Bioorg Med Chem Lett; 2008 Feb; 18(4):1419-24. PubMed ID: 18226901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda6-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones: Part 4. Optimization of DMPK properties.
    Sergeeva MV; Zhou Y; Bartkowski DM; Nolan TG; Norris DA; Okamoto E; Kirkovsky L; Kamran R; Lebrun LA; Tsan M; Patel R; Shah AM; Lardy M; Gobbi A; Li LS; Zhao J; Bertolini T; Stankovic N; Sun Z; Murphy DE; Webber SE; Dragovich PS
    Bioorg Med Chem Lett; 2008 Jun; 18(11):3421-6. PubMed ID: 18442904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 5: Exploration of pyridazinones containing 6-amino-substituents.
    Dragovich PS; Blazel JK; Ellis DA; Han Q; Kamran R; Kissinger CR; LeBrun LA; Li LS; Murphy DE; Noble M; Patel RA; Ruebsam F; Sergeeva MV; Shah AM; Showalter RE; Tran CV; Tsan M; Webber SE; Kirkovsky L; Zhou Y
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5635-9. PubMed ID: 18796353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 3: Further optimization of the 2-, 6-, and 7'-substituents and initial pharmacokinetic assessments.
    Li LS; Zhou Y; Murphy DE; Stankovic N; Zhao J; Dragovich PS; Bertolini T; Sun Z; Ayida B; Tran CV; Ruebsam F; Webber SE; Shah AM; Tsan M; Showalter RE; Patel R; Lebrun LA; Bartkowski DM; Nolan TG; Norris DA; Kamran R; Brooks J; Sergeeva MV; Kirkovsky L; Zhao Q; Kissinger CR
    Bioorg Med Chem Lett; 2008 Jun; 18(11):3446-55. PubMed ID: 18457949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 4-(1,1-Dioxo-1,4-dihydro-1lambda6-benzo[1,4]thiazin-3-yl)-5-hydroxy-2H-pyridazin-3-ones as potent inhibitors of HCV NS5B polymerase.
    Ellis DA; Blazel JK; Webber SE; Tran CV; Dragovich PS; Sun Z; Ruebsam F; McGuire HM; Xiang AX; Zhao J; Li LS; Zhou Y; Han Q; Kissinger CR; Showalter RE; Lardy M; Shah AM; Tsan M; Patel R; LeBrun LA; Kamran R; Bartkowski DM; Nolan TG; Norris DA; Sergeeva MV; Kirkovsky L
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4628-32. PubMed ID: 18662878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Des-A-ring benzothiadiazines: inhibitors of HCV genotype 1 NS5B RNA-dependent RNA polymerase.
    Donner PL; Xie Q; Pratt JK; Maring CJ; Kati W; Jiang W; Liu Y; Koev G; Masse S; Montgomery D; Molla A; Kempf DJ
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2735-8. PubMed ID: 18362072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitors of HCV NS5B polymerase: synthesis and structure-activity relationships of N-1-benzyl and N-1-[3-methylbutyl]-4-hydroxy-1,8-naphthyridon-3-yl benzothiadiazine analogs containing substituents on the aromatic ring.
    Rockway TW; Zhang R; Liu D; Betebenner DA; McDaniel KF; Pratt JK; Beno D; Montgomery D; Jiang WW; Masse S; Kati WM; Middleton T; Molla A; Maring CJ; Kempf DJ
    Bioorg Med Chem Lett; 2006 Jul; 16(14):3833-8. PubMed ID: 16650984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-nucleoside inhibitors of HCV NS5B polymerase. Part 1: Synthetic and computational exploration of the binding modes of benzothiadiazine and 1,4-benzothiazine HCV NS5b polymerase inhibitors.
    Hendricks RT; Fell JB; Blake JF; Fischer JP; Robinson JE; Spencer SR; Stengel PJ; Bernacki AL; Leveque VJ; Le Pogam S; Rajyaguru S; Najera I; Josey JA; Harris JR; Swallow S
    Bioorg Med Chem Lett; 2009 Jul; 19(13):3637-41. PubMed ID: 19447623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitors of HCV NS5B polymerase: synthesis and structure-activity relationships of N-alkyl-4-hydroxyquinolon-3-yl-benzothiadiazine sulfamides.
    Krueger AC; Madigan DL; Jiang WW; Kati WM; Liu D; Liu Y; Maring CJ; Masse S; McDaniel KF; Middleton T; Mo H; Molla A; Montgomery D; Pratt JK; Rockway TW; Zhang R; Kempf DJ
    Bioorg Med Chem Lett; 2006 Jul; 16(13):3367-70. PubMed ID: 16650764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HCV NS5B polymerase inhibitors 3: Synthesis and in vitro activity of 3-(1,1-dioxo-2H-[1,2,4]benzothiadiazin-3-yl)-4-hydroxy-2H-quinolizin-2-one derivatives.
    Wang G; Zhang L; Wu X; Das D; Ruhrmund D; Hooi L; Misialek S; Ravi Rajagopalan PT; Buckman BO; Kossen K; Seiwert SD; Beigelman L
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4484-7. PubMed ID: 19497737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insight into the structural requirements of benzothiadiazine scaffold-based derivatives as hepatitis C virus NS5B polymerase inhibitors using 3D-QSAR, molecular docking and molecular dynamics.
    Zhang HX; Li Y; Wang X; Xiao ZT; Wang YH
    Curr Med Chem; 2011; 18(26):4019-28. PubMed ID: 21824089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined 3D-QSAR, molecular docking, molecular dynamics simulation, and binding free energy calculation studies on the 5-hydroxy-2H-pyridazin-3-one derivatives as HCV NS5B polymerase inhibitors.
    Yu H; Fang Y; Lu X; Liu Y; Zhang H
    Chem Biol Drug Des; 2014 Jan; 83(1):89-105. PubMed ID: 23941500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5,5'- and 6,6'-dialkyl-5,6-dihydro-1H-pyridin-2-ones as potent inhibitors of HCV NS5B polymerase.
    Ellis DA; Blazel JK; Tran CV; Ruebsam F; Murphy DE; Li LS; Zhao J; Zhou Y; McGuire HM; Xiang AX; Webber SE; Zhao Q; Han Q; Kissinger CR; Lardy M; Gobbi A; Showalter RE; Shah AM; Tsan M; Patel RA; LeBrun LA; Kamran R; Bartkowski DM; Nolan TG; Norris DA; Sergeeva MV; Kirkovsky L
    Bioorg Med Chem Lett; 2009 Nov; 19(21):6047-52. PubMed ID: 19796938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pyrrolo[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase.
    Ruebsam F; Webber SE; Tran MT; Tran CV; Murphy DE; Zhao J; Dragovich PS; Kim SH; Li LS; Zhou Y; Han Q; Kissinger CR; Showalter RE; Lardy M; Shah AM; Tsan M; Patel R; Lebrun LA; Kamran R; Sergeeva MV; Bartkowski DM; Nolan TG; Norris DA; Kirkovsky L
    Bioorg Med Chem Lett; 2008 Jun; 18(12):3616-21. PubMed ID: 18487044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HCV NS5B polymerase inhibitors 1: Synthesis and in vitro activity of 2-(1,1-dioxo-2H-[1,2,4]benzothiadiazin-3-yl)-1-hydroxynaphthalene derivatives.
    Wang G; He Y; Sun J; Das D; Hu M; Huang J; Ruhrmund D; Hooi L; Misialek S; Ravi Rajagopalan PT; Stoycheva A; Buckman BO; Kossen K; Seiwert SD; Beigelman L
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4476-9. PubMed ID: 19502055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hexahydro-pyrrolo- and hexahydro-1H-pyrido[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase.
    Ruebsam F; Sun Z; Ayida BK; Webber SE; Zhou Y; Zhao Q; Kissinger CR; Showalter RE; Shah AM; Tsan M; Patel R; Lebrun LA; Kamran R; Sergeeva MV; Bartkowski DM; Nolan TG; Norris DA; Kirkovsky L
    Bioorg Med Chem Lett; 2008 Sep; 18(18):5002-5. PubMed ID: 18722768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening of hepatitis C NS5B polymerase inhibitors containing benzothiadiazine core: a steered molecular dynamics.
    Nutho B; Meeprasert A; Chulapa M; Kungwan N; Rungrotmongkol T
    J Biomol Struct Dyn; 2017 Jun; 35(8):1743-1757. PubMed ID: 27236925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HCV NS5B polymerase inhibitors 2: Synthesis and in vitro activity of (1,1-dioxo-2H-[1,2,4]benzothiadiazin-3-yl) azolo[1,5-a]pyridine and azolo[1,5-a]pyrimidine derivatives.
    Wang G; Lei H; Wang X; Das D; Hong J; Mackinnon CH; Coulter TS; Montalbetti CA; Mears R; Gai X; Bailey SE; Ruhrmund D; Hooi L; Misialek S; Rajagopalan PT; Cheng RK; Barker JJ; Felicetti B; Schönfeld DL; Stoycheva A; Buckman BO; Kossen K; Seiwert SD; Beigelman L
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4480-3. PubMed ID: 19500983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Molecular Field Analysis and Molecular Docking Studies on Quinolinone Derivatives Indicate Potential Hepatitis C Virus Inhibitors.
    Malathi K; Ramaiah S; Anbarasu A
    Cell Biochem Biophys; 2019 Jun; 77(2):139-156. PubMed ID: 30796723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.